Related Experiment Video
Updated: Feb 9, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults
Aysun Benli1, Serap Şimşek-Yavuz2, Seniha Başaran2
1Muş State Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Muş, Turkey
Objective:
We aimed to find the incidence and risk factors of hematologic adverse effects of piperacillin-tazobactam (TZP).
Materials And Methods:
Adult patients who used TZP for more than 10 days were included in the study.
Results:
The incidence of leukopenia, neutropenia, and eosinophilia in 110 TZP therapy episodes was found to be 16.3%, 10%, and 10%, respectively. Lower Charlson Comorbidity Index score, lower initial leukocyte count, combination of TZP with another antibiotic, and total duration of TZP therapy were found to be independent risk factors for leukopenia, while initial higher eosinophil count (IHEC) and usage of TZP for >20 days were independent risk factors for neutropenia and IHEC and total duration of TZP therapy were independent risk factors for eosinophilia.
Conclusion:
Longer duration of therapy, combination with other antibiotics, younger age with fewer comorbidities, and IHEC could result in hematologic adverse effects in patients treated with TZP. Patients with IHEC may be more prone to allergic reactions, so immunological mechanisms may facilitate the development of hematological adverse effects of TZP.
Insights
Piperacillin-tazobactam (TZP) can cause hematologic adverse effects like leukopenia and neutropenia. Risk factors include longer therapy duration and combination with other antibiotics, especially in younger patients.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Piperacillin-tazobactam (TZP) is a widely used antibiotic.
- Hematologic adverse effects are potential complications of antibiotic therapy.
- Understanding the incidence and risk factors of these effects is crucial for patient safety.
Purpose of the Study:
- To determine the incidence of hematologic adverse effects associated with piperacillin-tazobactam (TZP) therapy.
- To identify independent risk factors contributing to these adverse effects.
Main Methods:
- Retrospective study of adult patients receiving TZP for over 10 days.
- Analysis of 110 TZP therapy episodes.
- Statistical identification of risk factors for leukopenia, neutropenia, and eosinophilia.
Main Results:
- Incidence rates: leukopenia (16.3%), neutropenia (10%), eosinophilia (10%).
- Independent risk factors for leukopenia: lower Charlson Comorbidity Index, lower initial leukocyte count, combination therapy, longer TZP duration.
- Independent risk factors for neutropenia: higher initial eosinophil count (IHEC), TZP >20 days.
- Independent risk factors for eosinophilia: IHEC, longer TZP duration.
Conclusions:
- Longer TZP duration, combination therapy, younger age, fewer comorbidities, and IHEC are associated with hematologic adverse effects.
- Immunological mechanisms, potentially linked to allergic reactions in patients with IHEC, may underlie these effects.
Related Concept Videos
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Adult Stem Cells

